Life Science Daily News launched in November 2025 with a simple premise: that researchers, biotech founders, healthcare professionals, communications specialists and industry professionals should be able to publish their own work directly to a specialist audience, with editorial support rather than editorial selection, and without requiring a media budget to be heard. Eight months on, the platform has grown into an active, global community. This article sets out where we stand today, what the platform offers, and how professionals across the life sciences sector can contribute.
Why Life Science Daily News Was Built
The founding rationale was straightforward. Traditional life science trade publications typically operate behind a combination of paywalls, advertising dependencies and editorial selection processes that can delay or prevent the publication of timely, expert-led content. For researchers seeking to share findings in an accessible format, or for biotech start-ups wanting to announce a milestone to the right audience, the options have historically been limited to generic press release wires, social media posts or high-cost media placements.
The platform was designed as an alternative: a contributor-led publication built exclusively for the life sciences industry, where professionals submit their own work and every article is editorially reviewed before publication. Contributors can publish for free under the Explorer plan, with optional paid tiers available for those who want promotional content, backlinks and faster turnaround. Every article submission, regardless of plan, is held to the same quality and accuracy standards. The site carries no banner advertising, and editorial decisions are made independently of commercial relationships.
Growth Since Launch
The numbers from the first eight months of operation illustrate the pace at which the platform has grown. Almost 500 articles have been published since the November 2025 launch, with consistent month-on-month growth in both readership and contributor registrations. The site now attracts readers from over 100 countries worldwide, with active user numbers growing substantially each month.
In search visibility, the platform now ranks on the first page of Google for competitive terms including “life science news” and “life science news distribution” placing it alongside established titles in the sector. On social media, the publication’s LinkedIn page has grown to more than 800 followers.
These figures are notable for a publication that is less than a year old and operating without the institutional backing, legacy subscriber bases or advertising revenue that support larger trade media competitors in the space.
Louise Howard, Executive Editor of Life Science Daily News, said:
“The growth we have seen since November has been remarkable, but what makes it meaningful is the community behind it. Working alongside researchers, healthcare professionals and innovators from across the life sciences is a privilege, and some of the work being shared on this platform is truly humbling. From gene therapies that could transform the lives of children to AI-driven drug discovery that will shape how we treat disease for generations to come, our contributors are at the forefront of science that matters.”
What Life Science Daily News Covers
The platform publishes across six specialist categories: Biotech, Pharma, Clinical Trials, Regulatory, Health Tech and News. Coverage spans drug approvals and regulatory decisions, clinical trial data, biopharma mergers and acquisitions, health technology developments, and policy changes affecting the life sciences sector across the globe.
The editorial team produces two weekly features. The Weekly News Roundup summarises the most significant developments in pharma, biotech and healthcare, with recent editions covering the FDA’s expansion of the first CRISPR gene therapy to children, landmark oncology data presented at ASCO 2026, blockbuster acquisition activity from companies such as AbbVie, GSK and Merck KGaA, and first-in-class regulatory approvals across cell therapy and infectious disease. The Clinical Trials Roundup tracks notable trial readouts, regulatory milestones and pipeline developments across therapeutic areas.
Contributors publish across these categories, covering subjects from clinical research and drug development strategy to workplace wellbeing in healthcare and the economics of gene therapy reimbursement.
How the Contributor Model Works
Contributors register on the platform, draft their articles using a purpose-built template, and submit them for review. The editorial team assesses every submission for relevance, accuracy and adherence to house style before approving it for publication. All contributors are published under their own byline, with an author profile including biography, headshot and links to their professional profile.
Turnaround times vary by plan. Explorer articles are published within seven days, Pulse subscribers receive a three-day turnaround, and one-off Guest Posts and Press Releases are published within 24 hours. Once an article is approved, it is published on the platform and promoted across the publication’s social media channels.
Articles are expected to be between 800 and 1,500 words, with a maximum of 2,000 words. A feature image is required, and additional supporting visuals are encouraged. References are welcomed. Full editorial standards and style guidance are set out in the platform’s Contributor Policy.
Publishing Plans
The platform offers free and paid publishing options. The Explorer plan allows contributors to publish non-promotional, expert-led articles at no cost. For professionals and teams who want to include promotional content, branded backlinks or faster turnaround, paid options are available through the Pulse subscription at £95 p/m, one-off Guest Post at £95 and Press Release at £30. Full details and pricing are available on the membership page.
Long-Term Visibility
Every article published on the platform remains permanently live and indexed, with no expiry, no paywall and no archive cutoff. For contributors, this means that content continues to attract readers and build visibility long after its initial publication date.
Who Is Contributing
The contributor base spans a wide range of professional backgrounds. Independent researchers use the platform to share findings and build visibility outside traditional academic publishing channels. Biotech and start-up founders publish to announce milestones, explain their technology or provide market commentary. Healthcare professionals contribute clinical and practice-based perspectives. Communications specialists, including PR agencies, medical communications teams and university communications offices, publish on behalf of clients and institutions.
Contributor articles have covered subjects ranging from the first reported reversal of Alzheimer’s biomarkers linked to Lyme disease treatment to how AI will reshape life sciences in 2026, global funding shifts redrawing the innovation map, and why hormone tracking is emerging as a key health trend.
Don’t wait for the media to pick up your story. Be the media.
Researchers, biotech founders, healthcare professionals, communications specialists and industry professionals who want to share their expertise with a global life sciences readership can register and begin publishing at lifesciencedaily.news/join-publish. Whether the goal is to build professional visibility, distribute a press release, share original research in an accessible format or simply add an informed voice to the conversation, the platform is open and the audience is growing.
For media enquiries or to discuss a contribution, contact the editorial team at info@lifesciencedaily.news.
